SAN FRANCISCO, Oct. 20, 2022 (GLOBE NEWSWIRE) — Feel Therapeutics Inc., a number one digital precision drugs firm in psychological well being, in the present day introduced the latest granting by the United States Patent and Trademark Office of US Patent No. 11,410,682 entitled “Method for detecting and recognizing an emotional state of a user”.
The emotion detection expertise developed by Feel Therapeutics relies on superior machine studying and sign processing algorithms and strategies. These algorithms analyze important indicators and determine patterns that correspond to particular feelings to supply customized assist or therapeutic interventions. The expertise passively and repeatedly data physiological indicators by means of a wearable gadget worn by the consumer, in addition to knowledge from voice and different digital sources from the cell phone and Feel Therapeutics’ utility. To obtain excessive precision measurement of the temper state of the consumer the wearable gadget incorporates a steady electrodermal exercise (EDA) sensor developed by Feel Therapeutics.
“This patent reflects Feel’s commitment to enabling a new era of digital precision medicine in psychiatry, neuroscience, and beyond. It is part of a larger patent portfolio and intellectual property that the company has developed over the years,” mentioned Dr. Haris Tsirmpas, co-founder and CTO of Feel Therapeutics. “Powered by our large scale machine learning experimentation and psychophysiology analysis platform, this technology is addressing an urgent medical need by providing continuous, personalized, and timely support to individuals suffering from mental disorders.”
Enabling digital precision drugs for psychological well being by offering steady, customized, and proactive assist and interventions
The advantages of real-time emotion detection are quite a few for each people and psychological well being suppliers alike. The expertise affords steady, passive, and goal knowledge monitoring on the emotional state of a consumer, together with contextual info. This info permits healthcare suppliers to maintain monitor of the customers’ progress, and determine potential dangers in between appointments. Based on this, the Feel Rx+ and DTx applications present just-in-time and customized assist to people battling psychological well being points by triggering the well timed supply of acceptable therapeutic or assist actions, to keep away from deterioration of signs or potential ER visits and rehospitalizations.
This expertise has confirmed to be extremely efficient, as evidenced by a latest research revealed in Frontiers in Digital Health which assessed the feasibility, engagement, and preliminary medical outcomes of Feel’s program for nervousness and melancholy. Notably, this research additionally demonstrated a very excessive common precision degree (87%) in figuring out emotional occasions passively utilizing Feel’s emotion detection expertise.
An necessary milestone in Feel Therapeutics’ mental property portfolio
“We recently saw companies such as Amazon focusing on developing emotion detection wearable devices using voice recognition, and companies such as Fitbit and Verily monitoring stress and other health markers with electrodermal activity sensing,” mentioned George Eleftheriou, CEO and co-founder of Feel Therapeutics. “This showcases the importance of securing this patent for Feel Therapeutics in a booming market, and the importance of having developed a solid technology to translate digital data and physiological signals into precise metrics and insights related to mental health.”
Feel additionally has one other 4 pending patents for additional customized, data-driven, precision therapeutics and diagnostics within the subject of psychiatry and neuroscience.
About Feel Therapeutics
Feel Therapeutics, Inc. is creating Digital Biomarkers and Therapeutics to deliver goal knowledge and measurement into the way in which we diagnose, handle, and care for psychological well being. The firm is backed by top-tier buyers (Felicis, Anthemis, SOSV) and has partnerships with massive pharmaceutical firms to develop novel digital biomarkers and convey digital well being options to market as standalone applications or alongside medicines. Feel Therapeutics is headquartered in San Francisco, with extra places of work in Europe. For extra info, go to http://www.feeltherapeutics.com.
